Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV

Given the low incidence of cryptococcosis in HIV-infected children, even during the era before combination antiretroviral therapy (cART), management of this disease in this age group has not been prospectively studied. Treatment recommendations largely reflect information extrapolated from many well-designed studies involving HIV-infected adults with cryptococcal meningitis.¹

Epidemiology

Most cases of cryptococcosis in HIV-infected patients are caused by Cryptococcus neoformans; Cryptococcus gattii (formerly Cryptococcus neoformans variety gattii) infection occurs primarily in tropical and subtropical areas. Cryptococcal infections occur much less frequently in HIV-infected children than in adults.^2-5 During the pre-cART era, most cases of cryptococcosis in HIV-infected children (overall incidence, 1%) occurred in those aged 6 through 12 years and in those with CD4 T lymphocyte (CD4) cell counts indicating severe immunosuppression.⁴ Access to cART has further decreased the overall incidence of cryptococcal infection^6,7 in HIV-infected children. Data from Pediatric AIDS Clinical Trials Group studies before and after the advent of cART indicate that the rate of invasive fungal infection, including cryptococcosis, has remained <0.1 per 100 child-years.^8,9

Clinical Manifestations

Cryptococcosis often presents with subtle and non-specific findings, such as fever and headache. Early diagnosis requires consideration of this infection in symptomatic patients whose CD4 counts indicate severe immunosuppression. In both HIV-infected adults and children, meningoencephalitis is the most common initial manifestation of cryptococcosis. The disease typically evolves over days to weeks with fever and headache. Less frequent findings include nuchal rigidity, photophobia, and focal neurologic signs, as were seen among 30 HIV-infected children with cryptococcosis reported from the United States.⁴ In contrast to this indolent presentation, children in Zimbabwe presented with an acute form of neurologic cryptococcosis (69% with nuchal rigidity, 38% with seizure activity, and 23% with focal neurologic signs).¹⁰C. gattii infections occur mostly in people who are not HIV-infected (or do not have other immunocompromsing conditions), and neurologic disease due to C. gattii in such apparently normal hosts responds more slowly to treatment and results in high risk of neurologic complications.¹¹C. gattii infections in HIV-infected patients, however, are uncommon and are similar in presentation to C. neoformans infections in HIV-infected hosts.¹²

Disseminated cryptococcosis can be associated with cutaneous lesions, including small, translucent, umbilicated papules (indistinguishable from molluscum contagiosum), nodules, ulcers, and infiltrated plaques resembling cellulitis. Pulmonary cryptococcosis without dissemination is unusual in children. Presenting findings include unexplained recurrent fever, cough with scant sputum, intrathoracic lymphadenopathy, and focal or diffuse pulmonary infiltrates. The infection also can be asymptomatic, with pulmonary nodules revealed on routine chest radiograph.³

Diagnosis

Detection of cryptococcal antigen in serum, cerebrospinal fluid (CSF) or other body fluids is highly effective for rapid and accurate diagnosis of cryptococcal infection.

A lumbar puncture should be done in any patient with suspected cryptococcal meningitis. CSF cell count, glucose, and protein can be virtually normal with central nervous system (CNS) cryptococcosis, but the opening pressure usually is elevated. Microscopic examination of CSF on India ink-stained wet mounts can be performed to diagnose suspected CNS disease but is largely replaced with the use of the cryptococcal antigen test. In more than 90% of patients with cryptococcal meningitis, cryptococcal antigen can be detected in CSF or serum by latex agglutination test (available from several manufacturers).

Fungal cultures from CSF, sputum, and blood can identify the organism. In some cases (meaning refractory or relapsed disease), susceptibility testing of the C. neoformans isolate can be beneficial. Overall, in vitro resistance to antifungal agents remains uncommon.¹³

Diffuse pulmonary disease can be diagnosed through bronchoalveolar lavage and direct examination of India ink-stained specimens, culture, and antigen detection. Focal pulmonary and skin lesions may require biopsy with culture and staining.

Prevention Recommendations

Preventing Exposure

No strategies have been proven to prevent exposure. C. neoformans infection is believed to be acquired through inhalation of aerosolized particles from the environment. Serologic studies of immunocompetent children in an urban setting indicate that most children have been infected by C. neoformans by the third year of life.¹⁴

Preventing the First Episode of Disease

Because the incidence of cryptococcal disease is so low in HIV-infected children,^2-4,15 routine testing of asymptomatic children for serum cryptococcal antigen is not recommended (CIII).

A review of randomized controlled trials using antifungal interventions for the primary prevention of cryptococcal diseases indicates that fluconazole and itraconazole can reduce cryptococcal disease in adults who have advanced HIV disease and severe immunosuppression (CD4 count <50 cells/mm³).¹⁶ However, neither of these interventions clearly affected mortality.

In addition, routine use of antifungal medications is not recommended for primary prophylaxis of cryptococcal infections in children because of the low incidence of cryptococcosis in HIV-infected children, lack of survival benefits in primary prevention studies of adults,¹⁶ possibility of drug interaction, potential resistance to antifungal drugs, and cost (BIII). Early diagnosis of HIV infection and treatment with cART (following current HIV treatment guidelines) to prevent or reverse immune suppression should further reduce risk of cryptococcal disease in HIV-infected children.

Discontinuing Primary Prophylaxis

Not applicable.

Treatment Recommendations

Treating Disease

Note: These recommendations are largely based on high-quality evidence from studies in adults.

CNS Disease

The most common and well-studied presentation of cryptococcal infection in HIV-infected patients is CNS disease. In light of studies in adults,^17-19 combination therapy with amphotericin B deoxycholate (or liposomal amphotericin B) and flucytosine for 2 weeks (induction therapy) followed by fluconazole for a minimum of 8 weeks (consolidation therapy) is recommended for children (AI*). Amphotericin B lipid complex is an alternative to amphotericin B deoxycholate (BII*).²⁰ CSF was sterilized significantly more rapidly in adults with CNS cryptococcal disease who received initial therapy with amphotericin B deoxycholate (0.7 mg/kg/day) and flucytosine (100 mg/kg/day) than in those who received amphotericin B deoxycholate alone, amphotericin B deoxycholate plus fluconazole, or triple-antifungal therapy.^21,22 In one study of adults, liposomal amphotericin B (AmBisome®) dosed at 4 mg/kg/day resulted in significantly earlier CSF culture conversion than did amphotericin B deoxycholate at 0.7 mg/kg/day.²³ However, a randomized, double-blind clinical trial before the routine availability of cART that compared amphotericin B (0.7 mg/kg/day), liposomal amphotericin B (3 mg/kg/day), and liposomal amphotericin B (6 mg/kg/day) showed no difference in efficacy among the three arms, but significantly fewer adverse events with liposomal amphotericin B (3 mg/kg body weight/day).²⁴ Cost considerations aside (liposomal amphotericin is significantly more expensive than amphotericin B deoxycholate), based on the reported experience in adults, liposomal amphotericin B would be preferable to amphotericin B deoxycholate in patients with cryptococcal meningitis who have or are at risk of renal failure (AI*). Amphotericin B lipid complex is another option (BII*).²⁰ Monitoring for and managing increased intracranial pressure (ICP) is crucial to optimal management of CNS cryptococcosis (see below).

In patients who cannot tolerate flucytosine (or if flucytosine is not available), amphotericin B deoxycholate (or its liposomal preparation) with or without fluconazole can be used for initial therapy (BI*). In a randomized Phase II trial in HIV-infected adolescents and adults, amphotericin B deoxycholate plus high-dose fluconazole (800 mg daily) was found to be well tolerated and with a trend toward better outcome at days 42 and 70, compared with amphotericin B deoxycholate alone.²⁵ Studies are needed to further validate the use of this combination. In another study 80 HIV-seropositive, antiretroviral (ARV)-naive adults presenting with cryptococcal meningitis were randomized to 4 treatment arms of 2-week duration: group 1, amphotericin B (0.7–1 mg/kg) and flucytosine (25 mg/kg 4 times daily); group 2, amphotericin B (0.7–1 mg/kg) and fluconazole (800 mg daily); group 3, amphotericin B (0.7–1 mg/kg) and fluconazole (600 mg twice daily); and group 4, amphotericin B (0.7–1 mg/kg) and voriconazole (300 mg twice daily). The primary end point was the rate of clearance of infection from CSF or early fungicidal activity, as determined by results of serial, quantitative CSF cryptococcal cultures. There were no statistically significant differences in the rate of clearance of cryptococcal colony-forming units (CFU) in CSF samples among the 4 treatment groups.²⁶ Fluconazole plus flucytosine is superior to fluconazole alone^27,28 and provides an alternative to amphotericin B deoxycholate for acute therapy of invasive disease (BII*) that should be used only if amphotericin B-based therapy is not tolerated. Although fluconazole monotherapy was an effective alternative to amphotericin B in adults with AIDS-associated cryptococcal meningitis,²⁹ concerns in this study about differences in early death, delayed CSF sterilization, and drug resistance^30,31 make fluconazole monotherapy less favorable for initial therapy of CNS disease. Because of rapidly developing resistance, flucytosine alone should never be used to treat cryptococcosis. Echinocandins are not active against cryptococcal infections and should not be used (AIII).

After a minimum of 2 weeks of induction therapy with evidence of clinical improvement and a negative CSF culture after repeat lumbar puncture, amphotericin B deoxycholate (or its liposomal preparation) and flucytosine can be discontinued and consolidation therapy for a minimum of 8 weeks initiated with fluconazole (AI*).³² Itraconazole is a less preferable alternative to fluconazole for the consolidation phase of CNS therapy (BI*). Fluconazole is preferred because studies comparing the two agents demonstrate higher rates of CSF sterilization during consolidation therapy¹⁸ and less frequent relapse³² during maintenance therapy in fluconazole recipients. After completion of consolidation therapy, secondary prophylaxis (maintenance therapy or suppressive therapy) should be initiated (see below).

Pulmonary and Extra Pulmonary Cryptococcosis (CNS Disease Ruled Out)

No controlled clinical studies describe the outcome of non-CNS cryptococcosis in HIV-infected patients. CNS disease should be ruled out in all patients, after which the choice of antifungal medication and length of initial therapy can be decided in light of the clinical severity of illness. Patients with severe pulmonary disease or disseminated cryptococcosis should be treated with a form of amphotericin B with or without the addition of flucytosine, as for CNS disease (AIII). Usually combination therapy should be provided until symptoms resolve. Those with mild-to-moderate pulmonary illness or other localized disease can be managed with fluconazole monotherapy (AIII). Regardless of the antifungal agent selected for initial therapy, secondary prophylaxis with fluconazole or itraconazole should be provided as for CNS disease (AIII) (see notes below on secondary prophylaxis).

Monitoring and Adverse Events (Including IRIS)

Monitoring for Raised Intracranial Pressure

At the time of diagnosis and on subsequent lumbar punctures, all patients with cryptococcal meningitis should have their lumbar opening pressure measured. Studies in adults clearly show the role of increased ICP in deaths associated with CNS cryptococcosis.^18,33 Patients with severe headache, confusion, blurred vision, papilledema, or other neurologic signs or symptoms of increased ICP should be managed using measures to decrease ICP. One approach recommended for adults is to measure pressure continually or repeatedly during the lumbar puncture procedure and to remove CSF until the pressure is approximately half the opening pressure but still no lower than normal.³⁴ This may be repeated as often as every day until symptoms and signs consistently improve. Similar data describing experience with therapeutic lumbar punctures in children with cryptococcal meningitis are not available. Not specific to cryptococcal meningitis, a cutoff opening pressure of 28 cm of water has been proposed in children, above which the pressure should be considered elevated.³⁵ CSF shunting through a lumbar drain or ventriculostomy can be considered for patients who continue to have symptomatic increased ICP despite multiple lumbar taps (BIII). Corticosteroids and mannitol have been shown to be ineffective in managing ICP in adults with cryptococcal meningitis and most experts would not recommend their use in children (CIII). Acetazolamide is hazardous as therapy for increased ICP management in adults without signs of immune reconstitution inflammatory syndrome (IRIS) and has not been evaluated in children with cryptococcal meningitis; acetazolamide is not recommended for adults and most experts would similarly not use it in children (BIII).

Monitoring Treatment Response

In addition to monitoring clinical response, mycological response in patients with CNS cryptococcosis typically is assessed by a repeat lumbar puncture and CSF examination at 2 weeks of treatment, with continuation of induction therapy until CSF culture is negative.

Monitoring serial serum cryptococcal antigen titers is not useful for following treatment efficacy because changes in serum cryptococcal antigen titers do not correlate well with outcome during treatment for acute meningitis or during suppressive therapy.^36,37 Serial measurement of CSF cryptococcal antigen is more useful; in one study, an unchanged or increased titer of antigen in CSF correlated with clinical and microbiologic treatment failure, and a rise in CSF antigen titer during suppressive therapy was associated with relapse of cryptococcal meningitis.³⁶ However, monitoring of CSF cryptococcal antigen levels requires repeated lumbar punctures and is not routinely recommended for monitoring response.

Monitoring for Adverse Events

Adverse effects of amphotericin B (Table 5) are primarily nephrotoxicity; permanent nephrotoxicity is related to cumulative dose. Infusion-related fevers, chills, nausea, and vomiting can occur, but they are less frequent in children than in adults. Close monitoring for drug toxicities is needed especially when amphotericin B is used with flucytosine.

Flucytosine has the potential for marked toxicity, especially affecting the bone marrow (meaning anemia, leukopenia, and thrombocytopenia), liver, gastrointestinal (GI) tract, kidney, and skin. In patients receiving flucytosine, flucytosine blood levels should be monitored to prevent bone marrow suppression and GI toxicity; after 3–5 days of therapy, the target 2-hour post-dose serum level of flucytosine is 40–60 µg/mL. Flucytosine should be avoided in children with severe renal impairment.

Fluconazole and the other azoles have relatively low rates of toxicity, but their potential drug interactions can limit their use. Because of their ability to inhibit the CYP450-dependent hepatic enzymes, the potential for drug interactions, particularly with ARV drugs, should be carefully evaluated before initiation of therapy. Liver function tests should be monitored during treatment.

Immune Reconstitution Inflammatory Response Syndrome (IRIS)

While cases of IRIS in HIV-infected children have been described,³⁸ most of the available information comes from adult literature.

IRIS related to cryptococcosis can present within weeks (such as meningitis) or months (such as lymphadenitis) after start of cART. Symptoms of meningitis are similar to those described for meningitis presenting as the initial manifestation of cryptococcosis. In one study, about 30% of all HIV-infected adults hospitalized for infection with C. neoformans who received cART were re-admitted with symptoms attributed to an inflammatory response.³⁹ Of the 18 patients with C. neoformans-related IRIS in the cited study, 17 had culture-negative meningitis, and most cases occurred during the first 30 days after initiation of cART. The most common presentation of late cryptococcal IRIS is lymphadenitis, particularly mediastinal lymphadenitis.^40,41

IRIS is a clinical diagnosis. While there are no specific laboratory tests to diagnose IRIS, presence of negative cultures in a patient with clinical signs suggestive of tissue inflammation in the face of rapidly improving cellular immunity would be suggestive of IRIS over treatment failure. The optimal management of cryptococcal IRIS has not been defined. Antifungal therapy should be initiated in patients not already receiving it, raised intracranial pressure managed if present and antiretroviral therapy (ART) should be continued. Although many cases resolve spontaneously, some experts also have used anti-inflammatory therapy (e.g., short-course corticosteroids) in patients with severely symptomatic IRIS (CIII).^40,42

Adult HIV-infected treatment-naive patients with cryptococcal meningitis who go on to develop IRIS after starting cART are more likely to have higher HIV RNA levels at baseline⁴³ and exhibit less initial CSF inflammation at the time of cryptococcal meningitis diagnosis, compared with those who do not develop IRIS.⁴⁴ In patients with advanced immunosuppression and non-tuberculous opportunistic infections (OIs), the presence of a fungal infection, lower CD4 counts and higher HIV RNA levels at baseline, and higher CD4 counts and lower HIV RNA levels on treatment were found associated with IRIS.⁴³ For patients not on cART at the time of diagnosis of cryptococcal meningitis, the timing of cART in relation to antifungal treatment remains controversial. One randomized trial of adult HIV-infected patients with OIs (excluding tuberculosis) primarily from the United States that included 35 patients with cryptococcal meningitis suggested that early cART treatment (within the first 14 days of diagnosis) was safe and resulted in less AIDS progression/death compared to deferred cART.⁴⁵ However a randomized clinical trial in Zimbabwe was reported to show higher mortality in patients receiving cART starting within 72 hours of diagnosis compared to those waiting at least 10 weeks to initiate ART.⁴⁶ Patients in this study were treated with high dose fluconazole. Differences in management of cryptococcal meningitis, raised ICP, and cART treatment options may account for some of the differences between these two studies. In ARV-naive patients newly diagnosed with cryptococcal meningitis or disseminated disease, delay in potent ART may be prudent until the end of the first 2 weeks of induction therapy (CIII); further delays in initiating cART, especially in resource-poor settings, should be individualized.

Managing Treatment Failure

Treatment failure is defined as worsening or lack of improvement in signs and symptoms after 2 weeks of appropriate therapy, including management of ICP; or relapse after an initial clinical response. Differentiating IRIS from treatment failure is important because treatment approaches and outcomes differ; persistent positive cultures indicate treatment failure. Optimal management of patients with treatment failure is unknown. If cultures remain positive, evaluation of antifungal susceptibilities can be considered, although C. neoformans resistance to fluconazole is rare in the United States. Patients in whom initial azole-based therapy fails should be switched to amphotericin B-based therapy,³⁰ ideally in combination with flucytosine; the possibility of drug interactions resulting in sub-therapeutic azole levels (meaning concurrent rifampin use or other drugs metabolized by the liver) should be explored.³⁰ Use of liposomal amphotericin B should be considered, because one study suggests improved efficacy in CSF sterilization with liposomal preparations than with standard amphotericin B.²³ Some data from HIV-infected adults indicate higher dosages (meaning 400–800 mg/day) of fluconazole in combination with flucytosine also can be considered for salvage therapy.^19,47 Clinical experience with new antifungal agents in managing cryptococcosis is limited. A few patients with cryptococcal infections refractory or intolerant to standard antifungal therapy have been treated with posaconazole or voriconazole with variable success.^48,49

Preventing Recurrence (Secondary Prophylaxis)

Patients who have completed initial therapy for cryptococcosis should receive secondary prophylaxis (maintenance therapy or suppressive therapy) (AI*). Fluconazole (AI*) is superior and preferable to itraconazole (BI*) for preventing relapse of cryptococcal disease.^32,50,51

Discontinuing Secondary Prophylaxis (Maintenance or Suppressive Therapy)

Until recently, lifelong secondary prophylaxis typically was recommended. The safety of discontinuing secondary prophylaxis for cryptococcosis after immune reconstitution with cART has not been studied in children, and decisions in that regard should be made on a case-by-case basis. Adults who have successfully completed a course of initial therapy (including ≥12 months of secondary prophylaxis), remain asymptomatic with regard to signs and symptoms of cryptococcosis, and have a sustained (≥6 months) increase in their CD4 counts to ≥100 cells/mm³ with an undetectable viral load on ART for >3 months after cART are at apparent low risk of recurrence of cryptococcosis.^52-54 In light of these observations and inference from data regarding discontinuing secondary prophylaxis for other OIs in adults with advanced HIV infection, discontinuing secondary prophylaxis for cryptococcosis (after receiving secondary prophylaxis for at least 1 year) can be considered for asymptomatic children aged ≥6 years, with increase in their CD4 counts to ≥100 cells/mm³ and an undetectable viral load on cART for ≥3 months (CIII). Secondary prophylaxis should be re-initiated if the CD4 count decreases to <100 cells/mm³ (AIII). Most experts would not discontinue secondary prophylaxis for patients younger than age 6 years (CIII).

References

1. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. Feb 1 2010;50(3):291-322. Available at http://www.ncbi.nlm.nih.gov/pubmed/20047480.
2. Leggiadro RJ, Kline MW, Hughes WT. Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J. Sep 1991;10(9):658-662. Available at http://www.ncbi.nlm.nih.gov/pubmed/1923678.
3. Gonzalez CE, Shetty D, Lewis LL, Mueller BU, Pizzo PA, Walsh TJ. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. Sep 1996;15(9):796-800. Available at http://www.ncbi.nlm.nih.gov/pubmed/8878224.
4. Abadi J, Nachman S, Kressel AB, Pirofski L. Cryptococcosis in children with AIDS. Clin Infect Dis. Feb 1999;28(2):309-313. Available at http://www.ncbi.nlm.nih.gov/pubmed/10064249.
5. Likasitwattanakul S, Poneprasert B, Sirisanthana V. Cryptococcosis in HIV-infected children. Southeast Asian J Trop Med Public Health. Dec 2004;35(4):935-939. Available at http://www.ncbi.nlm.nih.gov/pubmed/15916094.
6. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis. Mar 15 2003;36(6):789-794. Available at http://www.ncbi.nlm.nih.gov/pubmed/12627365.
7. Dromer F, Mathoulin-Pelissier S, Fontanet A, et al. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS. Feb 20 2004;18(3):555-562. Available at http://www.ncbi.nlm.nih.gov/pubmed/15090810.
8. Dankner WM, Lindsey JC, Levin MJ, Pediatric ACTGPT. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. Jan 2001;20(1):40-48. Available at http://www.ncbi.nlm.nih.gov/pubmed/11176565.
9. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. Jul 19 2006;296(3):292-300. Available at http://www.ncbi.nlm.nih.gov/pubmed/16849662.
10. Gumbo T, Kadzirange G, Mielke J, Gangaidzo IT, Hakim JG. Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome. Pediatr Infect Dis J. Jan 2002;21(1):54-56. Available at http://www.ncbi.nlm.nih.gov/pubmed/11791100.
11. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. Jul 1995;21(1):28-34; discussion 35-26. Available at http://www.ncbi.nlm.nih.gov/pubmed/7578756.
12. Morgan J, McCarthy KM, Gould S, et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis. Oct 15 2006;43(8):1077-1080. Available at http://www.ncbi.nlm.nih.gov/pubmed/16983624.
13. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol. May 2005;43(5):2163-2167. Available at http://www.ncbi.nlm.nih.gov/pubmed/15872236.
14. Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics. May 2001;107(5):E66. Available at http://www.ncbi.nlm.nih.gov/pubmed/11331716.
15. Nesheim SR, Kapogiannis BG, Soe MM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics. Jul 2007;120(1):100-109. Available at http://www.ncbi.nlm.nih.gov/pubmed/17606567.
16. Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev. 2005(3):CD004773. Available at http://www.ncbi.nlm.nih.gov/pubmed/16034947.
17. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. Jul 19 1979;301(3):126-131. Available at http://www.ncbi.nlm.nih.gov/pubmed/449951.
18. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. Jul 3 1997;337(1):15-21. Available at http://www.ncbi.nlm.nih.gov/pubmed/9203426.
19. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. Apr 2000;30(4):710-718. Available at http://www.ncbi.nlm.nih.gov/pubmed/10770733.
20. Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis. 2005;40(Suppl: 6):S409-413. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15809927 
21. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. May 29 2004;363(9423):1764-1767. Available at http://www.ncbi.nlm.nih.gov/pubmed/15172774.
22. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, French Cryptococcosis Study G. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. Feb 2007;4(2):e21. Available at http://www.ncbi.nlm.nih.gov/pubmed/17284154.
23. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. Oct 1997;11(12):1463-1471. Available at http://www.ncbi.nlm.nih.gov/pubmed/9342068.
24. Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. Jul 15 2010;51(2):225-232. Available at http://www.ncbi.nlm.nih.gov/pubmed/20536366.
25. Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. Jun 15 2009;48(12):1775-1783. Available at http://www.ncbi.nlm.nih.gov/pubmed/19441980.
26. Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. Jan 1 2012;54(1):121-128. Available at http://www.ncbi.nlm.nih.gov/pubmed/22052885.
27. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. Oct 1994;19(4):741-745. Available at http://www.ncbi.nlm.nih.gov/pubmed/7803641.
28. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis. Jun 1998;26(6):1362-1366. Available at http://www.ncbi.nlm.nih.gov/pubmed/9636863.
29. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. Jan 9 1992;326(2):83-89. Available at http://www.ncbi.nlm.nih.gov/pubmed/1727236.
30. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis. Oct 15 2006;43(8):1069-1073. Available at http://www.ncbi.nlm.nih.gov/pubmed/16983622.
31. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. Jul 1 2007;45(1):76-80. Available at http://www.ncbi.nlm.nih.gov/pubmed/17554704.
32. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. Feb 1999;28(2):291-296. Available at http://www.ncbi.nlm.nih.gov/pubmed/10064246.
33. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. Jan 2000;30(1):47-54. Available at http://www.ncbi.nlm.nih.gov/pubmed/10619732.
34. Fessler RD, Sobel J, Guyot L, et al. Management of elevated intracranial pressure in patients with Cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol. Feb 1 1998;17(2):137-142. Available at http://www.ncbi.nlm.nih.gov/pubmed/9473014.
35. Avery RA, Shah SS, Licht DJ, et al. Reference range for cerebrospinal fluid opening pressure in children. N Engl J Med. Aug 26 2010;363(9):891-893. Available at http://www.ncbi.nlm.nih.gov/pubmed/20818852.
36. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis. May 1994;18(5):789-792. Available at http://www.ncbi.nlm.nih.gov/pubmed/8075272.
37. Aberg JA, Watson J, Segal M, Chang LW. Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease. HIV Clin Trials. Jul-Aug 2000;1(1):1-6. Available at http://www.ncbi.nlm.nih.gov/pubmed/11590483.
38. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J. Jan 2006;25(1):53-58. Available at http://www.ncbi.nlm.nih.gov/pubmed/16395104.
39. Shelburne SA, Darcourt J, White AC, et al. The role of immune reconstitution in¿ammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(7):1049-1052. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15825000 
40. Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect. Dec 2005;51(5):e289-297. Available at http://www.ncbi.nlm.nih.gov/pubmed/16321643.
41. Natukunda E, Musiime V, Ssali F, Kizito H, Kityo C, Mugyenyi P. A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child. AIDS Res Hum Retroviruses. Apr 2011;27(4):373-376. Available at http://www.ncbi.nlm.nih.gov/pubmed/21087142.
42. Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther. Jun 2006;4(3):469-478. Available at http://www.ncbi.nlm.nih.gov/pubmed/16771623.
43. Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One. 2010;5(7):e11416. Available at http://www.ncbi.nlm.nih.gov/pubmed/20617176.
44. Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis. Sep 15 2010;202(6):962-970. Available at http://www.ncbi.nlm.nih.gov/pubmed/20677939.
45. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575. Available at http://www.ncbi.nlm.nih.gov/pubmed/19440326.
46. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. Jun 1 2010;50(11):1532-1538. Available at http://www.ncbi.nlm.nih.gov/pubmed/20415574.
47. Lortholary O. Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries. Clin Infect Dis. Jul 1 2007;45(1):81-83. Available at http://www.ncbi.nlm.nih.gov/pubmed/17554705.
48. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. May 1 2003;36(9):1122-1131. Available at http://www.ncbi.nlm.nih.gov/pubmed/12715306.
49. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. Oct 2005;56(4):745-755. Available at http://www.ncbi.nlm.nih.gov/pubmed/16135526.
50. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. Feb 28 1991;324(9):580-584. Available at http://www.ncbi.nlm.nih.gov/pubmed/1992319.
51. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. Mar 19 1992;326(12):793-798. Available at http://www.ncbi.nlm.nih.gov/pubmed/1538722.
52. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med. Aug 20 2002;137(4):239-250. Available at http://www.ncbi.nlm.nih.gov/pubmed/12186514.
53. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis. May 15 2003;36(10):1329-1331. Available at http://www.ncbi.nlm.nih.gov/pubmed/12746781.
54. Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis. Feb 15 2004;38(4):565-571. Available at http://www.ncbi.nlm.nih.gov/pubmed/14765351.